Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of et

Trial Details

NCT ID
NCT06896916
Phase
PHASE1
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Etentamig
  • Iberdomide
Locations (sample)
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Denver, Colorado, United States|39.73915,-104.9847
  • St Louis, Missouri, United States|38.62727,-90.19789
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1.
  • Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol.
  • All participants must have measurable diseases per central laboratory as outlined in protocol

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →